Cogent Biosciences to Present Pivotal APEX Trial Data at EHA 2026
Event summary
- Cogent Biosciences will present pivotal APEX trial data on bezuclastinib for Advanced Systemic Mastocytosis (AdvSM) at EHA 2026.
- Oral presentation of APEX trial results scheduled for June 13, 2026, by Daniel DeAngelo, M.D., Ph.D.
- Poster presentations on bezuclastinib and JAK2 V617F program scheduled for June 12, 2026.
- EHA Congress will be held in Stockholm, Sweden, from June 11-14, 2026.
The big picture
Cogent Biosciences' presentations at EHA 2026 highlight its focus on precision therapies for genetically defined diseases. The company's bezuclastinib program targets the KIT D816V mutation in AdvSM, while its JAK2 V617F program aims to address myeloproliferative neoplasms. These presentations come at a time when the biotech industry is increasingly focused on developing targeted therapies for rare and genetically driven diseases.
What we're watching
- Clinical Validation
- How the APEX trial results will position bezuclastinib in the AdvSM treatment landscape.
- Pipeline Progress
- The pace at which Cogent can advance its JAK2 V617F program into clinical stages.
- Market Differentiation
- Whether Cogent can sustain competitive advantage with its precision therapies in genetically defined diseases.
Related topics